Integrated multi-omics analysis of adverse cardiac remodeling and metabolic inflexibility upon ErbB2 and ERRα deficiency

[1]  V. Giguère,et al.  Transcriptional control of energy metabolism by nuclear receptors , 2022, Nature Reviews Molecular Cell Biology.

[2]  J. Endo,et al.  Therapeutic Targets for DOX-Induced Cardiomyopathy: Role of Apoptosis vs. Ferroptosis , 2022, International journal of molecular sciences.

[3]  M. Bang,et al.  Understanding the Molecular Basis of Cardiomyopathy. , 2021, American journal of physiology. Heart and circulatory physiology.

[4]  A. Brazma,et al.  The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences , 2021, Nucleic Acids Res..

[5]  Amit Khurana,et al.  Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[6]  R. Ferreira,et al.  An update of the molecular mechanisms underlying doxorubicin plus trastuzumab induced cardiotoxicity. , 2021, Life sciences.

[7]  Y. Toropova,et al.  Analysis of Models of Doxorubicin-Induced Cardiomyopathy in Rats and Mice. A Modern View From the Perspective of the Pathophysiologist and the Clinician , 2021, Frontiers in Pharmacology.

[8]  P. Agrawal,et al.  Striated Preferentially Expressed Protein Kinase (SPEG) in Muscle Development, Function, and Disease , 2021, International journal of molecular sciences.

[9]  D. Kinnamon,et al.  The Complex and Diverse Genetic Architecture of Dilated Cardiomyopathy. , 2021, Circulation research.

[10]  A. Rodríguez-Sinovas,et al.  Connexins in the Heart: Regulation, Function and Involvement in Cardiac Disease , 2021, International journal of molecular sciences.

[11]  F. del Monte,et al.  The Heart of the Alzheimer's: A Mindful View of Heart Disease , 2021, Frontiers in Physiology.

[12]  Chunmei Geng,et al.  Systematic Evaluations of Doxorubicin-Induced Toxicity in Rats Based on Metabolomics , 2020, ACS omega.

[13]  J. Broxholme,et al.  Early detection of doxorubicin-induced cardiotoxicity in rats by its cardiac metabolic signature assessed with hyperpolarized MRI , 2020, Communications biology.

[14]  Maxim N. Artyomov,et al.  Open Source ImmGen: network perspective on metabolic diversity among mononuclear phagocytes , 2020, bioRxiv.

[15]  P. Oliveira,et al.  Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy. , 2020, Circulation research.

[16]  Claire O'Donovan,et al.  MetaboLights: a resource evolving in response to the needs of its scientific community , 2019, Nucleic Acids Res..

[17]  Li Ding,et al.  Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma , 2019, Cell.

[18]  Sumit Sharma,et al.  Molecular mechanism involved in cyclophosphamide‐induced cardiotoxicity: Old drug with a new vision , 2019, Life sciences.

[19]  P. Thavendiranathan,et al.  Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy. , 2019, The Canadian journal of cardiology.

[20]  L. Désaubry,et al.  Updates in Anthracycline-Mediated Cardiotoxicity , 2018, Front. Pharmacol..

[21]  William Stafford Noble,et al.  MoMo: Discovery of statistically significant post-translational modification motifs , 2018, bioRxiv.

[22]  C. Maack,et al.  Metabolic remodelling in heart failure , 2018, Nature Reviews Cardiology.

[23]  Ming Yan,et al.  Divergent Role of Estrogen-Related Receptor α in Lipid- and Fasting-Induced Hepatic Steatosis in Mice. , 2018, Endocrinology.

[24]  S. Auerbach,et al.  Identification of Estrogen-Related Receptor &agr; Agonists in the Tox21 Compound Library , 2018, Endocrinology.

[25]  L. Mestroni,et al.  Dilated Cardiomyopathy: Genetic Determinants and Mechanisms , 2017, Circulation research.

[26]  S. Russell,et al.  Cardiotoxicity From Human Epidermal Growth Factor Receptor‐2 (HER2) Targeted Therapies , 2017, Journal of the American Heart Association.

[27]  M. Young,et al.  Metabolic Origins of Heart Failure , 2017, JACC. Basic to translational science.

[28]  R. Gerszten,et al.  The Emerging Role of Metabolomics in the Diagnosis and Prognosis of Cardiovascular Disease. , 2016, Journal of the American College of Cardiology.

[29]  Gianluigi Savarese,et al.  Global Public Health Burden of Heart Failure. , 2016, Cardiac failure review.

[30]  I. Miinalainen,et al.  VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection , 2016, Proceedings of the National Academy of Sciences.

[31]  M. Artyomov,et al.  Integrating immunometabolism and macrophage diversity. , 2016, Seminars in immunology.

[32]  Maxime Caron,et al.  ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer , 2016, Nature Communications.

[33]  Hong-Xia Wang,et al.  Protection against doxorubicin-induced myocardial dysfunction in mice by cardiac-specific expression of carboxyl terminus of hsp70-interacting protein , 2016, Scientific Reports.

[34]  Abhishek Kumar Jha,et al.  GAM: a web-service for integrated transcriptional and metabolic network analysis , 2016, Nucleic Acids Res..

[35]  J. Fuscoe,et al.  Early metabolomics changes in heart and plasma during chronic doxorubicin treatment in B6C3F1 mice , 2016, Journal of applied toxicology : JAT.

[36]  K. Margulies,et al.  Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure , 2016, Circulation.

[37]  X. Qin,et al.  (1)H NMR based metabolomic profiling revealed doxorubicin-induced systematic alterations in a rat model. , 2016, Journal of pharmaceutical and biomedical analysis.

[38]  D. Rosenbaum,et al.  Phosphorylation at Connexin43 Serine‐368 Is Necessary for Myocardial Conduction During Metabolic Stress , 2016, Journal of cardiovascular electrophysiology.

[39]  V. Giguère,et al.  Orphan Nuclear Receptor ERRα Controls Macrophage Metabolic Signaling and A20 Expression to Negatively Regulate TLR-Induced Inflammation. , 2015, Immunity.

[40]  S. Carr,et al.  The extracellular matrix: Tools and insights for the "omics" era. , 2015, Matrix biology : journal of the International Society for Matrix Biology.

[41]  Yachen Zhang,et al.  A Metabolomic Study of Rats with Doxorubicin-Induced Cardiomyopathy and Shengmai Injection Treatment , 2015, PloS one.

[42]  J. Bamburg,et al.  Cofilin-2 phosphorylation and sequestration in myocardial aggregates: novel pathogenetic mechanisms for idiopathic dilated cardiomyopathy. , 2015, Journal of the American College of Cardiology.

[43]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[44]  V. Giguère,et al.  The multiple universes of estrogen-related receptor α and γ in metabolic control and related diseases , 2014, Acta Pharmacologica Sinica.

[45]  V. Giguère,et al.  ERBB2 Deficiency Alters an E2F-1-Dependent Adaptive Stress Response and Leads to Cardiac Dysfunction , 2014, Molecular and Cellular Biology.

[46]  Harold F. Gómez,et al.  Genomic Models of Short-Term Exposure Accurately Predict Long-Term Chemical Carcinogenicity and Identify Putative Mechanisms of Action , 2014, PloS one.

[47]  K. Naka,et al.  Oleuropein prevents doxorubicin-induced cardiomyopathy interfering with signaling molecules and cardiomyocyte metabolism. , 2014, Journal of molecular and cellular cardiology.

[48]  Travis J Cohoon,et al.  D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice , 2014, Genes & development.

[49]  M. Volpe,et al.  Natriuretic peptides in cardiovascular diseases: current use and perspectives. , 2014, European heart journal.

[50]  V. Giguère,et al.  Loss of estrogen-related receptor α promotes hepatocarcinogenesis development via metabolic and inflammatory disturbances , 2013, Proceedings of the National Academy of Sciences.

[51]  V. Giguère,et al.  The PGC-1/ERR signaling axis in cancer , 2013, Oncogene.

[52]  Edward Y. Chen,et al.  Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.

[53]  T. Marwick,et al.  Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. , 2012, Journal of the American College of Cardiology.

[54]  V. Giguère,et al.  Oestrogen-related receptors in breast cancer: control of cellular metabolism and beyond , 2012, Nature Reviews Cancer.

[55]  E. Yeh,et al.  Identification of the molecular basis of doxorubicin-induced cardiotoxicity , 2012, Nature Medicine.

[56]  Uwe Schlattner,et al.  Cardiac phosphoproteome reveals cell signaling events involved in doxorubicin cardiotoxicity. , 2012, Journal of proteomics.

[57]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[58]  Z. Lou,et al.  Potential Biomarkers in Mouse Myocardium of Doxorubicin-Induced Cardiomyopathy: A Metabonomic Method and Its Application , 2011, PloS one.

[59]  Jeff S. Jasper,et al.  The metabolic regulator ERRα, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer. , 2011, Cancer cell.

[60]  N. Frangogiannis,et al.  Transforming growth factor (TGF)-β signaling in cardiac remodeling. , 2011, Journal of molecular and cellular cardiology.

[61]  W. Chan,et al.  Thrombopoietin protects against doxorubicin‐induced cardiomyopathy, improves cardiac function, and reversely alters specific signalling networks , 2011, European journal of heart failure.

[62]  S. Peng,et al.  Global gene expression profiles of MT knockout and wild-type mice in the condition of doxorubicin-induced cardiomyopathy. , 2011, Toxicology letters.

[63]  H. Askari,et al.  Identification of diaryl ether-based ligands for estrogen-related receptor α as potential antidiabetic agents. , 2011, Journal of medicinal chemistry.

[64]  T. Camenisch,et al.  ErbB signaling in cardiac development and disease. , 2010, Seminars in cell & developmental biology.

[65]  K. Gevaert,et al.  Improved visualization of protein consensus sequences by iceLogo , 2009, Nature Methods.

[66]  A. Tsantili-Kakoulidou,et al.  Metabonomic identification of novel biomarkers in doxorubicin cardiotoxicity and protective effect of the natural antioxidant oleuropein , 2009, NMR in biomedicine.

[67]  Avi Ma'ayan,et al.  KEA: kinase enrichment analysis , 2009, Bioinform..

[68]  V. Giguère.  Transcriptional control of energy homeostasis by the estrogen-related receptors. , 2008, Endocrine reviews.

[69]  M. Mann,et al.  PHOSIDA (phosphorylation site database): management, structural and evolutionary investigation, and prediction of phosphosites , 2007, Genome Biology.

[70]  F. Robert,et al.  Nuclear receptor ERR alpha and coactivator PGC-1 beta are effectors of IFN-gamma-induced host defense. , 2007, Genes & development.

[71]  Elizabeth Murphy,et al.  The nuclear receptor ERRalpha is required for the bioenergetic and functional adaptation to cardiac pressure overload. , 2007, Cell metabolism.

[72]  M. Blanchette,et al.  Genome-wide Orchestration of Cardiac Functions by the Orphan Nuclear Receptors ERRα and γ , 2007 .

[73]  S. Mathivanan,et al.  A curated compendium of phosphorylation motifs , 2007, Nature Biotechnology.

[74]  S. Gygi,et al.  An iterative statistical approach to the identification of protein phosphorylation motifs from large-scale data sets , 2005, Nature Biotechnology.

[75]  W. Muller,et al.  Modulation of Erbb2 signaling during development: a threshold level of Erbb2 signaling is required for development , 2004, Development.

[76]  Denis Richard,et al.  Reduced Fat Mass in Mice Lacking Orphan Nuclear Receptor Estrogen-Related Receptor α , 2003, Molecular and Cellular Biology.

[77]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[78]  Carmen Birchmeier,et al.  Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[79]  Susumu Minamisawa,et al.  ErbB2 is essential in the prevention of dilated cardiomyopathy , 2002, Nature Medicine.

[80]  C. Hudis,et al.  Cardiac dysfunction in the trastuzumab clinical trials experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  Kuo-Fen Lee,et al.  Requirement for neuregulin receptor erbB2 in neural and cardiac development , 1995, Nature.

[82]  C. Hoge,et al.  THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.

[83]  I. Arif,et al.  Metabolomics Of Metformin's Cardioprotective Effect In Acute Doxorubicin Induced- Cardiotoxicity In Rats , 2021 .

[84]  W. Muller,et al.  Transcriptional control of the ERBB2 amplicon by ERR α and PGC-1 β promotes mammary gland tumorigenesis , 2010 .